66th ASH Annual Meeting

You may search for particular presentations by typing key words, an author's name, or the title in the box below. You may specify the type of search, i.e. whether you want to see pages that contain any or all of the words you specify. The Boolean search option requires one of the keywords and, or, and not, as well as parentheses.

The search filters will allow you to restrict your search by date, session type, or abstract category and are all optional. Hold down the Ctrl key while selecting to choose more than one option in each list, or hold down the Shift key to select a range.

Search:

Restrict search results to:

Browse by Day

Wednesday, December 4, 2024
Thursday, December 5, 2024
Friday, December 6, 2024
Saturday, December 7, 2024
Sunday, December 8, 2024
Monday, December 9, 2024
Tuesday, December 10, 2024
Wednesday, December 11, 2024
Thursday, December 12, 2024
Friday, December 13, 2024

-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
denotes an abstract that is clinically relevant

No Restriction
Plenary
101. Red Cells and Erythropoiesis, Excluding Iron
102. Iron Homeostasis and Biology
112. Thalassemia and Globin Gene Regulation
113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational
114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological
201. Granulocytes, Monocytes, and Macrophages
203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders
301. Platelets and Megakaryocytes: Basic and Translational
311. Disorders of Platelet Number or Function: Clinical and Epidemiological
321. Coagulation and Fibrinolysis: Basic and Translational
322. Hemophilia A and B: Clinical and Epidemiological
323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological
330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational
331. Thrombotic Microangiopathies/Thrombocytopenias: Clinical and Epidemiological
332. Thrombosis and Anticoagulation: Clinical and Epidemiological
401. Blood Transfusion
501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational
503. Clonal Hematopoiesis, Aging, and Inflammation
506. Bone Marrow Microenvironment
508. Bone Marrow Failure: Acquired
509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital
602. Myeloid Oncogenesis: Basic
603. Lymphoid Oncogenesis: Basic
604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms
605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms
612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological
613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation
614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Minimal Residual Disease in Diagnosis and Prognosis
615. Acute Myeloid Leukemias: Clinical and Epidemiological
616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies
617. Acute Myeloid Leukemias: Commercially Available Therapies
618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis
619. Acute Myeloid Leukemias: Disease Burden and Minimal Residual Disease in Prognosis and Treatment
621. Lymphomas: Translational - Molecular and Genetic
621. Lymphomas: Translational – Molecular and Genetic
622. Lymphomas: Translational - Non-Genetic
622. Lymphomas: Translational – Non-Genetic
623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological
623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological
624. Hodgkin Lymphomas: Clinical and Epidemiological
625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological
626. Aggressive Lymphomas: Clinical and Epidemiological
627. Aggressive Lymphomas: Pharmacologic Therapies
628. Aggressive Lymphomas: Cellular Therapies
631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational
632. Chronic Myeloid Leukemia: Clinical and Epidemiological
634. Myeloproliferative Syndromes: Clinical and Epidemiological
636. Myelodysplastic Syndromes: Basic and Translational
637. Myelodysplastic Syndromes: Clinical and Epidemiological
641. Chronic Lymphocytic Leukemia: Basic and Translational
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational
652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological
653. Multiple Myeloma: Clinical and Epidemiological
654. Multiple Myeloma: Pharmacologic Therapies
655. Multiple Myeloma: Cellular Therapies
701. Experimental Transplantation: Basic and Translational
702. CAR-T Cell Therapies: Basic and Translational
703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational
704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities
711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities
722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution
723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence
732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies
801. Gene Therapies
802. Chemical Biology and Experimental Therapeutics
803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology
900. Health Services and Quality Improvement: Hemoglobinopathies
901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies
902. Health Services and Quality Improvement: Lymphoid Malignancies
903. Health Services and Quality Improvement: Myeloid Malignancies
904. Outcomes Research: Hemoglobinopathies
905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies
906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders
907. Outcomes Research: Plasma Cell Disorders
908. Outcomes Research: Myeloid Malignancies
909. Education, Communication, and Workforce
ASH-a-Palooza
Scientific Workshop on Aging and Hematology
Scientific Workshop on Challenges and Novel Technologies in Red Blood Cell Quality Assessment
Scientific Workshop on Clonal Hematopoiesis
Scientific Workshop on Decentralized Clinical Trials in Hematology: Reshaping the Traditional Clinical Trial Paradigm With AI Strategies for 'Real World' Patient Representation
Scientific Workshop on Genomic Toxicities of Gene and Cell Therapies
Scientific Workshop on Germline Predisposition to Hematopoietic Malignancies and Bone Marrow Failure
Scientific Workshop on Interplay Between Coagulation and Malignancy
Scientific Workshop on Mitochondria and Metabolism in Blood Cancer - From Discovery to Patients
Scientific Workshop on Therapy Resistance Mechanisms in Blood Malignancies
Scientific Workshop on Understanding and Overcoming Tumor-intrinsic Resistance to CAR-T Therapies for Lymphoid Malignancies
TiPs 1. TIPS-Classical Hematology
TiPs 2. TIPS-Lymphoid Malignancies
TiPs 3. TIPS-Myeloid Malignancies

No Restriction
Research
Research - Fundamental Science
Research - Translational Research
Research - Clinical Research
Research - Clinical Research - Clinical trials
Research - Clinical Research - Epidemiology
Research - Clinical Research - Health outcomes research
Research - Clinical Research - Health disparities research
Research - Clinical Research - Patient-reported outcomes
Research - Clinical Research - Real-world evidence
Research - Clinical Research - Registries
Research - Clinical Research - Survivorship
Clinical Practice (Health Services and Quality)
Workforce
Diversity, Equity, and Inclusion (DEI)
Education
Diseases
Diseases - Bleeding and Clotting
Diseases - Bleeding and Clotting - Bleeding disorders
Diseases - Bleeding and Clotting - Hemophilia
Diseases - Bleeding and Clotting - Platelet disorders
Diseases - Bleeding and Clotting - Thromboembolism
Diseases - Bleeding and Clotting - Thrombocytopenias
Diseases - Bleeding and Clotting - Thrombotic disorders
Diseases - Bleeding and Clotting - VWD
Diseases - Bone Marrow Failure Syndromes
Diseases - Bone Marrow Failure Syndromes - Acquired Marrow Failure Syndromes
Diseases - Bone Marrow Failure Syndromes - Inherited Marrow Failure Syndromes
Diseases - Bone Marrow Failure Syndromes - Aplastic Anemia
Diseases - Bone Marrow Failure Syndromes - Paroxysmal Nocturnal Hemoglobinuria
Diseases - Genetic Disorders
Diseases - Hemoglobinopathies
Diseases - Hemoglobinopathies - Sickle Cell Disease
Diseases - Hemoglobinopathies - Sickle Cell Trait
Diseases - Hemoglobinopathies - Thalassemia
Diseases - Immune Disorders
Diseases - Immune Disorders - Autoimmune disorders
Diseases - Immune Disorders - Autoimmune hemolytic anemia
Diseases - Immune Disorders - GVD
Diseases - Immune Disorders - GVHD
Diseases - Immune Disorders - Immunodeficiency
Diseases - Immune Disorders - Neutropenia
Diseases - Immune Disorders - White blood cell disorders
Diseases - Infectious Diseases
Diseases - Infectious Diseases - Viral
Diseases - Infectious Diseases - Bacterial
Diseases - Infectious Diseases - Fungal
Diseases - Infectious Diseases - Other Pathogens
Diseases - Infectious Diseases - SARS-CoV-2/COVID-19
Diseases - Lymphoid Malignancies
Diseases - Lymphoid Malignancies - Lymphoid Leukemias
Diseases - Lymphoid Malignancies - Lymphoid Leukemias - ALL
Diseases - Lymphoid Malignancies - Lymphoid Leukemias - CLL
Diseases - Lymphoid Malignancies - Lymphoid Leukemias - LGL
Diseases - Lymphoid Malignancies - Lymphomas
Diseases - Lymphoid Malignancies - Lymphomas - Hodgkin lymphoma
Diseases - Lymphoid Malignancies - Lymphomas - Non-Hodgkin lymphoma
Diseases - Lymphoid Malignancies - Lymphomas - B Cell lymphoma
Diseases - Lymphoid Malignancies - Lymphomas - T Cell lymphoma
Diseases - Lymphoid Malignancies - Lymphomas - Indolent lymphoma
Diseases - Lymphoid Malignancies - Lymphomas - Aggressive lymphoma
Diseases - Lymphoid Malignancies - Plasma Cell Disorders
Diseases - Myeloid Malignancies
Diseases - Myeloid Malignancies - Acute Myeloid Malignancies
Diseases - Myeloid Malignancies - Acute Myeloid Malignancies - AML
Diseases - Myeloid Malignancies - Acute Myeloid Malignancies - APL
Diseases - Myeloid Malignancies - Chronic Myeloid Malignancies
Diseases - Myeloid Malignancies - Chronic Myeloid Malignancies - MDS
Diseases - Myeloid Malignancies - Chronic Myeloid Malignancies - MPN
Diseases - Myeloid Malignancies - Chronic Myeloid Malignancies - CML
Diseases - Myeloid Malignancies - Chronic Myeloid Malignancies - CMML
Diseases - Metabolic Disorders
Diseases - Metabolic Disorders - Iron Deficiency
Diseases - Metabolic Disorders - Iron Overload
Treatment Considerations
Treatment Considerations - Combination therapy
Treatment Considerations - Drug development
Treatment Considerations - Drug-drug interactions
Treatment Considerations - Supportive Care
Treatment Considerations - Therapy sequence
Treatment Considerations - Biological therapies
Treatment Considerations - Biological therapies - Antibody Therapy
Treatment Considerations - Biological therapies - Bispecific Antibody Therapy
Treatment Considerations - Biological therapies - Chimeric Antigen Receptor (CAR)-T Cell Therapies
Treatment Considerations - Biological therapies - Checkpoint Inhibitor
Treatment Considerations - Biological therapies - Gene Therapy
Treatment Considerations - Biological therapies - Immunotherapy
Treatment Considerations - Biological therapies - Infusion
Treatment Considerations - Biological therapies - Monoclonal Antibody Therapy
Treatment Considerations - Biological therapies - Miscellaneous Cellular Therapies
Treatment Considerations - Biological therapies - Natural Killer (NK) Cell Therapies
Treatment Considerations - Biological therapies - Transfusion
Treatment Considerations - Biological therapies - Transplantation (Allogeneic and Autologous)
Treatment Considerations - Biological therapies - Vaccines
Treatment Considerations - Non-Biological therapies
Treatment Considerations - Non-Biological therapies - Anticoagulant Drugs
Treatment Considerations - Non-Biological therapies - Chemotherapy
Treatment Considerations - Non-Biological therapies - Coagulant Drugs
Treatment Considerations - Non-Biological therapies - Devices
Treatment Considerations - Non-Biological therapies - Opioids
Treatment Considerations - Non-Biological therapies - Palliative Care
Treatment Considerations - Non-Biological therapies - Pharmacology
Treatment Considerations - Non-Biological therapies - Surgical
Treatment Considerations - Non-Biological therapies - Radiation Therapy
Adverse Events
Biological Processes
Biological Processes - Apoptosis
Biological Processes - CHIP
Biological Processes - Genomics
Biological Processes - Hematopoiesis
Biological Processes - Immune mechanism
Biological Processes - Immunology
Biological Processes - Metabolism
Biological Processes - Microbiome
Biological Processes - Molecular biology
Biological Processes - Multi-systemic interactions
Biological Processes - Pathogenesis
Technology and Procedures
Technology and Procedures - Artificial intelligence (AI)
Technology and Procedures - Assays
Technology and Procedures - Bioinformatics
Technology and Procedures - Blood banking
Technology and Procedures - Cell expansion
Technology and Procedures - Clinical procedures
Technology and Procedures - Computational biology
Technology and Procedures - Emerging technologies
Technology and Procedures - Gene editing
Technology and Procedures - Profiling
Technology and Procedures - Imaging
Technology and Procedures - Machine learning
Technology and Procedures - Molecular testing
Technology and Procedures - Natural language processing
Technology and Procedures - Newborn Screening
Technology and Procedures - Omics technologies
Technology and Procedures - Pathology
Technology and Procedures - Serologic Tests
Study Population
Study Population - Human
Study Population - Human - Adult
Study Population - Human - Elderly
Study Population - Human - Embryo/fetus
Study Population - Human - Pediatric
Study Population - Human - Neonatal
Study Population - Human - Pregnant
Study Population - Human - Young adult
Study Population - Animal model
Measurable Residual Disease
Maternal Health

66th ASH Annual Meeting

Restrict search results to:

Meeting Program